Introduction and historical perspective
Prior to the past decade, little attention was paid to the control of hyperglycemia in the perioperative period or in the acute phase of critical illness managed in the ICU. Permissive or stress-induced hyperglycemia was generally accepted as the norm. Stress-induced hyperglycemia is defined as a transient response to the stress of an acute injury or illness [1] . Observational studies have reported significant prevalence of hyperglycemia in hospitalized patients [2] . Seventy percent of diabetic patients with acute coronary syndrome and 80% of cardiac surgery patients in the perioperative period may develop hyperglycemia [2] . With the advent of the new millennium came Van den Berghe's landmark study, published in 2001 [3] . For the first time, clinical research demonstrated a mortality benefit of tight glucose control in the ICU. From this study originated the concept of intensive insulin therapy (IIT) as a means of normalizing elevated glucose levels in critically ill patients. IIT is defined by a target glucose range of 80-110 mg/dl and standard care implies a target glucose range of 180-200 mg/dl in the early studies addressing this issue. Although Van den Berghe's study was a single-center, nonblinded trial, other retrospective studies also supported their findings and many centers adopted IIT protocols for management of hyperglycemia in the ICU. However, over the course of the next few years, several studies comparing IIT to standard care failed to demonstrate a difference with respect to mortality; the IIT groups also demonstrated high incidences of hypoglycemia (8-28%) [4] [5] [6] [7] [8] (Fig. 1) [4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
With the publication of these studies, the pendulum began to swing in the opposite direction. In March 2009, the normoglycemia in intensive care evaluationsurvival using glucose algorithm regulation (NICE-SUGAR) trial was published. This long-awaited study is the largest trial of tight glucose control in the ICU (6104 patients in 42 centers). Demonstrated was an absolute increase in mortality and an increased incidence of hypoglycemia in the IIT group compared with controls [17] . In the months following publication of this study, much of the related literature has focused on commentary and analysis of the results of the study.
Purpose of review
The publication of Van den Berghe's landmark study in 2001 supported the use of intensive insulin therapy (IIT) to target normoglycemia in the critically ill and triggered a new era in glycemic management in the perioperative period and in the ICU. In 2009, the normoglycemia in intensive care evaluation-survival using glucose algorithm regulation (NICE-SUGAR) trial demonstrated increased mortality and incidence of hypoglycemia in patients managed with IIT, resulting in a shift toward higher blood glucose targets in this patient population. This review distills clinically pertinent principles from the related literature published in the months since the NICE-SUGAR trial.
Recent findings
A target blood glucose level in the acute care setting supported by many of the pertinent societies and frequently quoted in the literature is 140-180 mg/dl. Hyperglycemia, hypoglycemia, and glucose variability are detrimental. Accurate and efficient glucose monitoring devices are essential. Insulin infusion protocols (IIPs) employed to achieve desired blood glucose targets must be individualized and validated for the ICU and institution in which they are being implemented. Summary Appropriate glycemic management in the acute care setting can be achieved by targeting a reasonable blood glucose range and employing specific and institutionally validated IIPs. This review will summarize the basic precepts of glycemic management in the perioperative and critically ill patient in the context of this new paradigm shift away from IIT since the publication of the NICE-SUGAR trial. The clinically relevant spectrum of glycemic derangement will be reviewed, as well as current and future trends in glucose monitoring. The rationale for the currently recommended target glucose range of 140-180 mg/dl will be highlighted. Finally, recommendations for glycemic management from leading societies will be outlined, emphasizing that each center should develop protocols that are evidence-based but also tailored to the needs and limitations of their respective institution.
Glycemic derangement: hyperglycemia, hypoglcymia and variability
The physiology of glycemic control is a complex cellular and neuroendocrine process well summarized in a recent review by Akhtar et al. [18 ] . Stress-induced hyperglycemia occurs in the perioperative period and in the critically ill. This phenomenon is mediated by numerous factors, not the least of which is the baseline metabolic condition of the patient. The neuroendocrine response (release of counterregulatory hormones including glucagon, epinephrine and cortisol) and insulin resistance are also key factors. Interestingly, hyperglycemia in ICU patients without diabetes results in poorer outcomes than in diabetic ICU patients [19] .
It is well established that diabetic patients are prone to perioperative cardiac complications because of underlying cardiovascular disease as well as surgical site infections due to immune dysfunction. However, hyperglycemia in nondiabetics also causes complications. Although a specific threshold at which hyperglycemia results in adverse effects is not established, some deleterious effects are reported at glucose concentrations > 200 mg/dl [18 ] . As is the case for diabetics, immunosuppression and an increase in circulating inflammatory cytokines occur in nondiabetic hyperglycemic critically ill patients. Consequently, increased rates of sepsis are one of the most common deleterious effects of hyperglycemia [20] [21] [22] . Vasoconstriction as well as osmotic diuresis leading to dehydration, electrolyte dyscrasias and acid-base disorders also occur, all of which lead to clinically significant issues. Hyperosmolality may lead to central nervous system dysfunction with resultant mental status changes and neurologic deficits, which may be lifethreatening [18 ] . An example of a less common occurrence reported recently is increased risk of liver allograft rejection following transplant in the setting of postoperative hyperglycemia [23] . The economic impact of hyperglycemia is significant, given the relationship between glycemic control and diabetes-related hospital costs [24] . Because of these well documented adverse outcomes, the
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Key points A reasonable target range for blood glucose concentration in the perioperative period and in the ICU is 140-180 mg/dl. Glucose variability may be an important factor influencing outcomes in this patient population. IIPs should be validated for use in the ICU and institution in which they are being implemented. Some of the major prospective studies in critically ill patients, which have led to current recommendations are as follows: [4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
current standard of care in the perioperative and critically ill patient population includes prevention and treatment of hyperglycemia [25] . However, even use of an IIT may not be effective in managing hyperglycemia [26] , and the problem is recalcitrant in some patients.
Hypoglycemia is a rare occurrence compared with hyperglycemia, but it is the principal factor limiting optimization of glycemic control. Hypoglycemia is also associated with increased mortality [27, 28, 29 ] . Clinically significant hypoglycemia is defined by Whipple's triad: symptoms of neuroglycopenia, simultaneous blood glucose concentration less than 40 mg/dl, and relief of symptoms with glucose administration. Although a subclinical stress response may be initiated at glucose levels less than 70 mg/dl, a blood glucose level of approximately 55 mg/dl results in activation of the sympathetic nervous system and autonomic symptoms, which include sweating, palpitations, tremor, and hunger. Neuroglycopenic symptoms occur with blood glucose levels of approximately 45 mg/ dl and include behavioral and cognitive impairment, drowsiness, speech difficulty, blurred vision, seizures, coma, and death [30] . Many of the autonomic as well as the early neurologic symptoms are notably absent in the intubated, sedated, critically ill, or anesthetized patient. Hypoglycemia is an independent predictor of mortality and has been a recurrent problem demonstrated in numerous studies evaluating IIT [31 ] . However, specific protocols vary in their risk of inducing hypoglycemia [32] .
Finally, glucose variability (changes in the measured level of blood glucose) is an independent predictor of mortality [33, 34] . This indicates that measures of glycemia other than glucose concentration may be important in the pathophysiology of hyperglycemia. Three different methods of expression of glucose variability are utilized: standard deviation (SD) of glucose, the mean amplitude of glycemic excursions (MAGE) and the glycemic lability index (GLI). SD is the square-root of the average of the squared differences between individual glucose values and the mean. MAGE is the mean of absolute values of any [Delta] glucose (consecutive values) that are greater than 1 SD of the entire set of glucose values. GLI is the squared difference between consecutive glucose measures per unit of actual time between those samples. Of these three methods, the GLI may be the best discriminator for mortality [35] . One concern regarding IIT is that it may increase glucose variability. However, no prospective trials have determined whether decreased glucose variability results in improved outcomes with IIT [36] .
Glycemic measurement: pitfalls and projections
Glucose concentrations are measured from blood obtained from arterial catheters, venous catheters or fingerstick devices. The glucometer is the measurement device that provides the fastest results but is least accurate. Degree of inaccuracy may be greater than 20% and is most likely to occur with lower glucose levels or if tissue edema, hypoperfusion, or anemia are present [31 ,36,37,38 ]. Blood gas analyzers are fast (if located in proximity to patient care areas) and accurate. Laboratory analysis is the most accurate but slowest method of blood glucose measurement [31 ] . Inaccuracy of conventional monitoring devices may lead to excessive insulin administration with resultant hypoglycemia. This is particularly dangerous in the ICU or operating room, where patients are typically intubated and sedated or anesthetized, conditions that limit clinical evaluation for hypoglycemia.
Advanced glucose monitoring technology and insulin delivery devices are forthcoming. Continuous glucose monitoring technology may improve glycemic control by decreasing glucose variability and hypoglycemia. However, further investigation is needed to determine which sensors are appropriate for use in the perioperative and ICU settings [39] . Subcutaneous glucose sensors typically display glucose readings every 5 min. However, because glucose concentration of the interstitial fluid is measured, hypoglycemia may be underestimated, given the lag time for equilibration of glucose concentrations between the vasculature and the interstitium [40] . Nonetheless, these devices appear to improve efficiency and workload burden [41] .
A subcutaneous insulin pump augmented with a continuous glucose monitor has been used for glycemic management of ST elevated myocardial infarction patients in a coronary care unit in a pilot trial. The technology significantly reduced the duration of hyperglycemia and plasma glucose levels. However, a small but significant increase in hypoglycemia compared with controls was noted [42] .
Taking the technology one step further is the artificial endocrine pancreas, a closed loop system that continuously samples peripheral venous blood for glucose monitoring. The system automatically infuses insulin and/or glucose to adjust the patient's blood glucose level. A Japanese group has utilized this technique in hepatic resection, pancreatic resection, esophageal resection, emergency surgeries, and cardiovascular operations [21, [43] [44] [45] .
Glyemic management: in the wake of NICE-SUGAR Several studies published subsequent to the NICE-SUGAR trial underscored the findings of that investigation. Annane et al. [46] found no reduction in mortality and increased hypoglycemia in a randomized controlled trial of IIT with glucocorticoids in the treatment of septic shock. The control group was given standard insulin therapy along with glucocorticoids. Three recent metaanalyses of randomized trials investigating IIT demonstrated no overall effect on mortality and increased hypoglycemia rates in the IIT groups compared with controls [47, 48, 49 ]. An observational cohort study published prior to the NICE-SUGAR trial compared outcomes before and after institution of an IIT policy. Hypoglycemia was increased and no survival benefit was noted with the institution of IIT [50] .
The NICE-SUGAR trial and other recent publications demonstrate that IIT does not improve survival, in fact it may increase mortality and is associated with more hypoglycemia than standard insulin therapy. This raises the obvious question: Where do we go from here? Given that in the NICE-SUGAR study, the standard insulin therapy control group (140-180 mg/dl range), had similar outcomes (if not better) than the IIT group, the 140-180 mg/dl range is now generally accepted as the new goal. On 8 May 2009 the American Association of Clinical Endocrinologists and the American Diabetes Association (AACE/ADA) released formal recommendations for the management of hyperglycemia in the ICU [51, 52] . The recommended threshold to initiate an insulin infusion is no higher than 180 mg/dl. Once insulin therapy has been initiated, the 140-180 mg/dl goal range is targeted.
Numerous current reviews cite this target range [2,31 ,53-56], although it must be remembered that an evidence-based universally appropriate target blood glucose range in the perioperative period or in the critically ill patient has yet to be determined. Additionally, although it is well established that hyperglycemia is associated with adverse perioperative outcomes, the abrogating impact of perioperative glycemic control has yet to be precisely established [10] .
In addition to the AACE/ADA, various other professional organizations have published guidelines for the management of glucose levels in the ICU. The Surviving Sepsis Campaign targets a blood glucose level of 150 mg/dl; the Institute for Healthcare Improvement target is less than 180 mg/dl; the European Society of Cardiology and European Association for the Study of Diabetes targets 'strict' control, although their guidelines have not been updated since the NICE-SUGAR trial was published [31 ] . However, the 2009 European Society of Cardiology guidelines for perioperative cardiac management in noncardiac surgery patients do take into account the results of the NICE-SUGAR study and recommend maintaining glucose levels less than 180 mg/dl in postsurgery patients [57] . The Canadian Diabetes Association targets a level of less than 110 mg/dl in critically ill patients; these guidelines have likewise not been updated subsequent to publication of the NICE-SUGAR trial [58] . The American Heart Association/American College of Cardiology targets 110-180 mg/dl in patients undergoing noncardiac surgery [59] ; again, this predates the NICE-SUGAR trial. The Society of Thoracic Surgeons (for cardiac surgery) targets 150-180 mg/dl [60] , while the most recent guidelines from the American College of Physicians recommend keeping glucose less than 180 mg/dl, in critically ill patients (Table 1) [61 ] .
Practical considerations
Achieving ideal glycemic control in the perioperative period and in the critically ill is challenging [62] . Glucoregulation in critically ill patients is dependent on multiple factors. These include variations in glucose intake, route of glucose intake (enteral versus parenteral), glucose absorption, endogenous insulin secretion, exogenous insulin administration, insulin kinetics, basal variations in insulin sensitivity, and perturbations of insulin action at the organ level [63] . Nonetheless, the recent literature does not support IIT to achieve normoglycemia (blood glucose level < 110 mg/dl) in the perioperative period or in the critically ill. Since the publication of the NICE-SUGAR trial, a commonly employed target range for blood glucose in critically-ill patients is 140-180 mg/dl. In more general terms, maintaining blood glucose levels less than 180 mg/dl in the perioperative period and in the critically ill is supported by the majority of the societies that have updated their recommendations since the publication of the NICE-SUGAR trial [10] .
Perioperative glycemic management in 2011 Maerz and Akhtar 373 In general, subcutaneous insulin administration is not recommended for glycemic management in the perioperative period or in the critically ill. Absorption is unpredictable because of variability in skin perfusion. Additionally, onset of action of subcutaneous formulations may be variable and is usually too slow to produce the desired effect in a timely manner in this patient population [64] . Most effective insulin infusion protocols (IIPs) in the acute care setting use continuous IV insulin infusion, sometimes combined with bolus intravenous injections. IIPs target a desired glucose level below a certain number (for instance, below 180 mg/dl). The protocol calculations incorporate measurement of glucose concentration and rate of change. An IIP chosen for a particular institution or ICU must be tested and reviewed in that setting. Criteria for use of the IIP must be developed and should specify insulin concentration and a glucose target range. Development of a safety strategy for prevention, detection and treatment of hypoglycemia is necessary. A quality improvement process is essential to ensure appropriate training, maintenance of competence, development of standards in the management of the IIP, and to provide a process through which errors can be analyzed, addressed, and prevented from recurring [31 ] . Frequently forgotten and usually underappreciated is the fact that insulin is one of the most potent and dangerous medications that we administer routinely in the acute care setting.
It is essential that the IIP and standards surrounding its use be tailored and individualized to the requirements, limitations, staffing, and patient population of the ICU and institution in which the IIP is being implemented. In particular, adequate resources should be allocated to ensure that goals of therapy are being safely achieved [31 ] .
Conclusion
In the decade since the publication of Van den Berghe's landmark study supported the use of IIT to achieve normoglycemia in the critically ill, glycemic management in the perioperative period and in the ICU has undergone a paradigm shift. The publication of the NICE-SUGAR trial in 2009 and other studies in that time frame has resulted in widespread adoption of higher blood glucose targets in this patient population. Many societies support a target range of 140-180 mg/dl. Recent literature indicates that glucose variability may be as important as, if not more important than, the absolute blood glucose level. More research is needed to better delineate these relationships. Accurate and efficient blood glucose monitoring equipment is an integral component of glycemic management; continuous glucose monitoring devices and other advances for use in the acute care setting are in various stages of development and testing.
IIPs are typically used for glycemic management in the perioperative period and in critically ill patients. These protocols and standards for utilization must be individualized and validated for use in the ICU and institution in which they are being implemented.
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